ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 214 filers reported holding ROYALTY PHARMA PLC in Q1 2021. The put-call ratio across all filers is 1.03 and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,476,669 | -12.0% | 1,638,787 | -0.3% | 0.01% | -9.1% |
| Q2 2023 | $50,519,796 | -18.2% | 1,643,455 | -4.1% | 0.01% | -21.4% |
| Q1 2023 | $61,755,419 | -11.8% | 1,714,000 | -3.3% | 0.01% | -12.5% |
| Q4 2022 | $70,048,093 | +4.8% | 1,772,472 | +6.5% | 0.02% | 0.0% |
| Q3 2022 | $66,847,000 | +14.5% | 1,663,697 | +19.8% | 0.02% | +23.1% |
| Q2 2022 | $58,363,000 | +24.5% | 1,388,303 | +15.3% | 0.01% | +44.4% |
| Q1 2022 | $46,892,000 | -12.6% | 1,203,632 | -10.6% | 0.01% | -10.0% |
| Q4 2021 | $53,679,000 | -12.8% | 1,347,015 | -20.9% | 0.01% | -16.7% |
| Q3 2021 | $61,546,000 | +51.2% | 1,702,989 | +71.4% | 0.01% | +50.0% |
| Q2 2021 | $40,716,000 | +9.3% | 993,306 | +16.4% | 0.01% | 0.0% |
| Q1 2021 | $37,239,000 | +57.4% | 853,715 | +80.6% | 0.01% | +60.0% |
| Q4 2020 | $23,658,000 | +119.8% | 472,690 | +84.8% | 0.01% | +66.7% |
| Q3 2020 | $10,763,000 | +332.2% | 255,837 | +398.8% | 0.00% | +200.0% |
| Q2 2020 | $2,490,000 | – | 51,286 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |